Archives
-
Protease Inhibitor Cocktail (MS-SAFE) Overview
2026-10-08
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO), SKU K4001, is an APExBIO-listed reagent described for limiting endogenous proteolysis during protein extraction. No matched paper evidence was provided, so its performance and mass-spectrometry benefits remain unverified here.
-
Glutathione Redox Signals in Hypoxic Tumors
2026-10-08
A mechanistic and translational perspective on how GSH and GSSG measurements can contextualize hypoxia, immunometabolism, oxidative stress, and tumor microenvironment biology without overstating what a bulk redox assay can prove.
-
Milk Extracellular Vesicles in Porcine Intestinal Models
2026-10-07
Wang et al. developed three porcine intestinal stem cell–based model formats to examine how milk-derived extracellular vesicles interact with regionally specified, polarized intestinal epithelium. The study links vesicle uptake to epithelial orientation and intestinal location, while showing that endocytosis inhibitors reduce internalization and that colon-derived models display changes in stemness- and differentiation-associated gene expression.
-
Protease Inhibitors in OXPHOS Cancer Research
2026-10-07
A source-grounded overview of how sample-preservation reagents relate to research on LRPPRC inhibition, dasatinib, and oxidative phosphorylation. The discussion separates findings from interpretation, explains where an EDTA-free protease inhibitor may support protein-analysis workflows, and outlines the evidence limitations that prevent direct claims about therapeutic efficacy or clinical translation.
-
dual-enSERT and In Vivo Enhancer Variant Testing
2026-10-06
Hollingsworth and colleagues introduce dual-enSERT, a two-color reporter framework for comparing human enhancer alleles in the same living mouse context. The study validates known regulatory variants, identifies activity-changing variants among 15 neurodevelopmental candidates, and combines reporter measurements with single-cell transcriptomics to connect enhancer activity with cellular states.
-
Protease Inhibitor Cocktail for OXPHOS Research
2026-10-06
A translational perspective on how proteolysis control supports interpretation of OXPHOS-focused cancer research, using the reported LRPPRC–dasatinib study as an anchor while defining evidence limits and the role of an EDTA-free protease inhibition strategy.
-
TSSK2 Inhibitors: Pyrimidine and Pyrrolopyrimidine Findings
2026-10-05
Hawkinson and colleagues reported a mobility-shift high-throughput screen that identified potent pyrrolopyrimidine and pyrimidine inhibitors of the reproductive kinase TSSK2. The study established sub-100-nanomolar biochemical inhibitors, including a compound with dual TSSK1/TSSK2 activity and reduced metabolic-liability concerns, while also defining important limits for translating enzyme potency into contraceptive efficacy.
-
In Vivo CAR T Cells for Lupus: Evidence and Limits
2026-10-05
A source-grounded overview of a 2026 mouse study evaluating in vivo generation of CD19-directed CAR T cells for systemic lupus erythematosus. The article explains the research context, reported immune and tissue outcomes, comparison with antibody-based and ex vivo CAR T approaches, and the major limitations affecting interpretation. It also clarifies that the supplied study does not identify the HyperScribe™ kit or establish that a commercial mRNA synthesis product was used.
-
Protease Inhibitor Cocktails: Evidence and Limits
2026-10-04
A source-grounded overview of how protease inhibitor cocktails may support protein stability in plant extracts, how to assess supplier claims, and why findings from TBK1–itaconic acid research should not be overextended across biological systems.
-
AEBSF.HCl and the Next Protease Question
2026-10-03
AEBSF.HCl offers a strategic way to interrogate serine-protease-dependent biology without confusing it with the cathepsin-driven lysosomal axis implicated in MLKL-associated necroptosis. This perspective connects protease mechanism, amyloid processing, cell-lysis studies, and translational evidence boundaries.
-
Polybrene: Reliable Transduction Workflows
2026-10-02
This scenario-based guide explains how Polybrene (Hexadimethrine Bromide) 10 mg/mL, SKU K2701, can help stabilize viral transduction and difficult lipid-mediated DNA transfection workflows without obscuring cell-toxicity effects. It provides practical controls, storage guidance, assay interpretation, and a candid framework for comparing reagent formats.
-
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag)
2026-10-01
R1078 enables controlled, transient display of mouse OX40L for mechanistic co-stimulation studies, with an HA tag that supports orthogonal expression checks. This guide separates directly supported product use from insights translated from CD80 and 4-1BBL mRNA work, then provides a practical workflow for assay design, optimization, and troubleshooting.
-
BIBR 1532: Telomerase Inhibitor Workflows
2026-10-01
Build a reproducible telomerase inhibition workflow with BIBR 1532, from concentration-response testing to orthogonal apoptosis and telomere-maintenance readouts. Its non-nucleosidic hTERT mechanism also provides a useful comparator for DNA-damage and telomere-attrition combinations in leukemia and solid-tumor models.
-
LRPPRC–Dasatinib Dual OXPHOS Disruption
2026-09-30
A 2026 study identified dasatinib as a synergistic partner for LRPPRC inhibition in OXPHOS-dependent cancer models. Its central mechanistic insight is that the combination blocks mitochondrial and nuclear OXPHOS programs in parallel, providing a rationale for dual-genome metabolic targeting while highlighting important translational questions.
-
Protease Inhibitor Cocktail: Assay Workflow Guide
2026-09-30
Learn how an EDTA-free inhibitor blend can protect protein extracts for Western blotting, immunoprecipitation, phosphorylation studies, and native-complex analysis. This workflow guide also explains how findings from a melatonin-loaded hydrogel study translate into better sample-preservation and assay-design decisions.